TG Therapeutics, Inc. TGTX
57.43
(0.09)
(0.16%)
as of 25 Sep
- Market cap
- $8.8B
- P/E
- 18.9×
Follow TGTX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
18.07 | 10.45 | 9.71 | 11.77 |
+8 more quarters Free account |
P/S ratio |
9.74 | 6.85 | 6.98 | 9.88 | |
P/FCF ratio |
448.02 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
198.38 | (268.15) | 218.82 | (226.92) | |
P/B ratio |
12.89 | 8.23 | 6.64 | 8.65 | |
Price to Tangible BV |
12.91 | 8.24 | 6.65 | 8.66 | |
EV/Sales |
9.99 | 7.18 | 7.15 | 10.09 | |
EV/EBITDA |
58.71 | 33.96 | 36.42 | 54.16 | |
EV/Operating CF |
446.60 | (360.58) | (177.91) | (76.62) | |
EV/FCF |
459.22 | (354.48) | (176.39) | (76.44) | |
Quick Ratio |
3.55 | 4.84 | 2.91 | 2.53 | |
Current Ratio |
4.27 | 5.81 | 4.10 | 3.82 | |
Net Debt/EBITDA |
8.87 | 6.63 | 2.05 | 3.93 | |
Debt/Assets |
45.46% | 48.74% | 23.10% | 23.94% | |
Debt/Equity |
1.23 | 1.28 | 0.38 | 0.40 | |
Asset Turnover |
0.68 | 0.64 | 0.75 | 0.66 | |
Operating CF/Net income |
5.05 | (0.90) | 0.85 | (0.06) | |
Capex/Depreciation |
(3.29) | 25.50 | 5.58 | 0.19 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
39.67% | 21.24% | 23.12% | 25.28% | |
Selling, General and Administrative Expense of Revenue |
34.17% | 45.43% | 30.85% | 39.19% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.60% | 9.74% | 8.13% | 10.94% | |
Graham Net Nets |
0.01 | 0.03 | 0.05 | 0.03 | |
Graham Number |
17.07 | 17.00 | 17.61 | 16.98 | |
Earnings Yield |
5.53% | 9.57% | 10.30% | 8.50% | |
Free Cash Flow Yield |
0.22% | (0.30%) | (0.58%) | (1.34%) | |
Revenue per Share |
1.70 | 1.42 | 1.33 | 1.11 | |
Operating CF per Share |
0.28 | (0.12) | 0.14 | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.27 | (0.12) | 0.14 | (0.16) | |
Cash per Share |
3.90 | 3.56 | 0.98 | 0.90 | |
Shareholders Equity per Share |
4.26 | 4.04 | 4.49 | 4.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.26 | 4.04 | 4.49 | 4.18 | |
Free Cash Flow |
38.97 | (17.94) | 19.59 | (23.23) | |
Working Capital |
877.19 | 899.86 | 477.00 | 442.96 | |
Capital Expenditures |
(0.29) | (0.05) | (0.07) | (0.08) | |
Net Current Asset Value |
110.14 | 141.26 | 215.53 | 181.96 | |
EV/EBIT |
58.56 | 33.65 | 35.74 | 52.24 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
3.24% | 9.65% | 11.96% | 241.73% | |
Price to Operating Income |
57.13 | 32.10 | 34.88 | 51.12 | |
| Other line items | |||||
Average Receivables |
316.54 | 291.08 | 217.41 | 190.56 | |
Average Payables |
173.86 | 141.39 | 82.90 | 106.87 | |
Average Inventory |
151.59 | 143.39 | 118.02 | 115.81 | |
Average Assets |
1,171.12 | 1,092.76 | 820.47 | 805.52 | |
Average Common Equity |
440.26 | 410.21 | 435.19 | 399.69 |
Columns are period end dates